Inari Medical, Inc. (NARI) Q3 2024 Earnings Call Transcript Summary
Inari Medical, Inc. (NARI) Q3 2024 Earnings Call Transcript Summary
The following is a summary of the Inari Medical, Inc. (NARI) Q3 2024 Earnings Call Transcript:
以下是inari medical, Inc. (NARI) 2024年第三季度業績會交易摘要:
Financial Performance:
金融業績:
Inari Medical reported a Q3 2024 revenue of $153.4 million, which is a 21% year-over-year growth.
Gross margin for Q3 2024 was 87.1%, slightly down from the prior year due to product mix and ramp-up costs associated with new products.
Operating expenses in Q3 2024 were $147.1 million, an increase primarily due to personnel-related expenses and a one-time non-cash impairment charge.
Despite a GAAP operating loss of $13.6 million, the non-GAAP operating loss was $0.4 million, showing significant improvement and movement towards profitability.
inari medical報告2024年第三季度營業收入15340萬美元,同比增長21%。
2024年第三季度的毛利率爲87.1%,略低於去年,主要是由於產品組合和與新產品相關的增長成本。
2024年第三季度的營業費用爲14710萬美元,主要增加是由於與人員相關的費用和一項一次性非現金減值損失。
儘管有1360萬美元的GAAP營業虧損,但非GAAP營業虧損爲40萬美元,顯示出明顯的改善和朝着盈利能力的發展。
Business Progress:
業務進展:
Inari Medical continues to focus on driving adoption of its PE and DVT therapies and emerging therapies portfolio.
Significant progress was made in the international business, with strong revenue growth driven by adoption in Europe and advances in regulatory approvals in Brazil, China, and Japan.
Announced the commencement of a limited market release of the next-gen Artix system in acute limb ischemia, expected to serve a $600 million U.S. TAM.
Introduced next-gen stent delivery system for LimFlow, aiming for broad commercialization in 2025, alongside enhanced inpatient and outpatient reimbursements.
inari medical繼續專注於推動其市盈率和DVt療法以及新興療法組合的採用。
在國際業務方面取得了重大進展,歐洲市場的強勁營業收入增長是驅動力,巴西、中國和日本在監管批准方面也有所進展。
宣佈在急性肢體缺血領域有限市場推出下一代Artix系統,預計將服務於60000萬美元的市場。
推出了面向LimFlow的下一代支架輸送系統,旨在在2025年實現廣泛商業化,同時增加住院和門診的報銷額。
Opportunities:
機會:
Ongoing commercial and market development efforts are expected to drive robust growth in the U.S. and international markets, particularly with the awaiting PEERLESS study data, which could potentially shift front-line treatment standards in VTE care.
Emerging therapies and international expansions signify strong growth potential, especially with regulatory progress in markets like China and Japan.
正在進行的商業和市場開發工作有望推動美國和國際市場的強勁增長,尤其是在等待PEERLESS研究數據的情況下,這些數據有可能改變深靜脈血栓(VTE)治療的一線標準。
新興療法和國際拓展標誌着強勁增長潛力,特別是在中國和日本等市場的監管進展方面。
Risks:
風險:
Growth from emerging therapies, such as Artix, expected to be gradual as these products undergo phased market introductions and gauging their market acceptance.
The reliance on PEERLESS study outcomes to potentially influence rapid adoption and standard treatment protocols for PE.
來源於新興療法(如Artix)的增長預計將是逐漸的,因爲這些產品正在經歷分階段的市場推介,並評估其市場接受程度。
依賴PEERLESS研究結果,有可能影響PE的快速採納和標準治療方案。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:如需更全面的詳情,請參閱投資人關係網站。本文僅供投資者參考,不作任何指引或建議。
譯文內容由第三人軟體翻譯。